Fresenius Medical Care Beheer
Beheer criteriumcontroles 1/4
De CEO Fresenius Medical Care is Helen Giza, benoemd in Nov2019, heeft een ambtstermijn van 4.92 jaar. De totale jaarlijkse vergoeding van { bedraagt € 5.53M, bestaande uit 30.1% salaris en 69.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.005% van de aandelen van het bedrijf, ter waarde € 485.55K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 0.8 jaar.
Belangrijke informatie
Helen Giza
Algemeen directeur
€5.5m
Totale compensatie
| Percentage CEO-salaris | 30.1% |
| Dienstverband CEO | 4.9yrs |
| Eigendom CEO | 0.005% |
| Management gemiddelde ambtstermijn | 1.9yrs |
| Gemiddelde ambtstermijn bestuur | less than a year |
Recente managementupdates
Recent updates
We Think Fresenius Medical Care (ETR:FME) Is Taking Some Risk With Its Debt
Sep 26
These Return Metrics Don't Make Fresenius Medical Care (ETR:FME) Look Too Strong
Sep 08At €34.34, Is Fresenius Medical Care AG (ETR:FME) Worth Looking At Closely?
Aug 20Fresenius Medical Care AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 02These 4 Measures Indicate That Fresenius Medical Care (ETR:FME) Is Using Debt Extensively
Jun 17What You Can Learn From Fresenius Medical Care AG's (ETR:FME) P/E
May 30Some Shareholders May Object To A Pay Rise For Fresenius Medical Care AG's (ETR:FME) CEO This Year
May 10Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.19
Apr 26Fresenius Medical Care's (ETR:FME) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 29Fresenius Medical Care (ETR:FME) Has Announced That It Will Be Increasing Its Dividend To €1.19
Mar 14Fresenius Medical Care's (ETR:FME) Dividend Will Be Increased To €1.19
Feb 23When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Feb 22Market Participants Recognise Fresenius Medical Care AG's (ETR:FME) Earnings
Feb 03Fresenius Medical Care (ETR:FME) Could Be Struggling To Allocate Capital
Jan 16Is Fresenius Medical Care (ETR:FME) Using Too Much Debt?
Dec 29Is There Now An Opportunity In Fresenius Medical Care AG & Co. KGaA (ETR:FME)?
Nov 21Capital Allocation Trends At Fresenius Medical Care KGaA (ETR:FME) Aren't Ideal
Oct 16Is Fresenius Medical Care KGaA (ETR:FME) A Risky Investment?
Sep 28Is Now The Time To Look At Buying Fresenius Medical Care AG & Co. KGaA (ETR:FME)?
Aug 21An Intrinsic Calculation For Fresenius Medical Care AG & Co. KGaA (ETR:FME) Suggests It's 34% Undervalued
Jul 23Returns On Capital At Fresenius Medical Care KGaA (ETR:FME) Paint A Concerning Picture
Jul 09These 4 Measures Indicate That Fresenius Medical Care KGaA (ETR:FME) Is Using Debt Extensively
Jun 25What Does Fresenius Medical Care AG & Co. KGaA's (ETR:FME) Share Price Indicate?
May 07Is There An Opportunity With Fresenius Medical Care AG & Co. KGaA's (ETR:FME) 49% Undervaluation?
Apr 23We Think Fresenius Medical Care KGaA (ETR:FME) Is Taking Some Risk With Its Debt
Mar 24Should You Think About Buying Fresenius Medical Care AG & Co. KGaA (ETR:FME) Now?
Feb 03Are Investors Undervaluing Fresenius Medical Care AG & Co. KGaA (ETR:FME) By 45%?
Jan 19Fresenius Medical Care KGaA (ETR:FME) Might Be Having Difficulty Using Its Capital Effectively
Jan 04Fresenius Medical Care KGaA (ETR:FME) Takes On Some Risk With Its Use Of Debt
Dec 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €530m |
| Mar 31 2024 | n/a | n/a | €484m |
| Dec 31 2023 | €6m | €2m | €499m |
| Sep 30 2023 | n/a | n/a | €450m |
| Jun 30 2023 | n/a | n/a | €596m |
| Mar 31 2023 | n/a | n/a | €602m |
| Dec 31 2022 | €3m | €1m | €673m |
| Sep 30 2022 | n/a | n/a | €763m |
| Jun 30 2022 | n/a | n/a | €806m |
| Mar 31 2022 | n/a | n/a | €878m |
| Dec 31 2021 | €2m | €855k | €969m |
| Sep 30 2021 | n/a | n/a | €918m |
| Jun 30 2021 | n/a | n/a | €998m |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €2m | €855k | €1b |
| Sep 30 2020 | n/a | n/a | €1b |
| Jun 30 2020 | n/a | n/a | €1b |
| Mar 31 2020 | n/a | n/a | €1b |
| Dec 31 2019 | €2m | €108k | €1b |
Compensatie versus markt: De totale vergoeding ($USD 6.00M ) Helen } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 5.06M ).
Compensatie versus inkomsten: De beloning van Helen is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Helen Giza (56 yo)
4.9yrs
Tenure
€5,528,000
Compensatie
Ms. Helen Giza is Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & Co. KGAA from December 6, 2022. She serve...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chair of Management Board & CEO | 4.9yrs | €5.53m | 0.0047% € 485.6k | |
| CFO & Member of the Management Board | less than a year | €887.00k | geen gegevens | |
| Global Chief Medical Officer & Member of Management Board | 4.8yrs | €3.13m | 0.0062% € 641.2k | |
| CEO of Care Enablement & Member of Management Board | 2.8yrs | €3.71m | 0.0039% € 401.5k | |
| CEO of Care Delivery & Member of Management Board | less than a year | geen gegevens | geen gegevens | |
| Executive VP and Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Global Head of Legal | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Corporate Communications & Governmental Affairs | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Research & Development | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Manufacturing and Supply Chain Operations | no data | geen gegevens | geen gegevens | |
| Senior Vice President - Quality Management International | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Western Europe & Nephrocare Coordination EMEALA | no data | geen gegevens | geen gegevens |
1.9yrs
Gemiddelde duur
56.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van FME wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Independent Member of Supervisory Board | less than a year | €20.00k | geen gegevens | |
| Chairman of the Supervisory Board | 1.3yrs | €444.00k | geen gegevens | |
| Independent Member of Supervisory Board | less than a year | €21.00k | geen gegevens | |
| Independent Member of Supervisory Board | 3.4yrs | €151.00k | geen gegevens | |
| Employee Representative Deputy Chairwoman of the Supervisory Board | less than a year | geen gegevens | geen gegevens | |
| Member of Supervisory Board | less than a year | €158.00k | geen gegevens | |
| Employee Representative Member of Supervisory Board | less than a year | geen gegevens | geen gegevens | |
| Employee Representative Member of the Supervisory Board | less than a year | geen gegevens | geen gegevens | |
| Employee Representative Member of the Supervisory Board | less than a year | geen gegevens | geen gegevens | |
| Employee representatives Member of the Supervisory Board | less than a year | geen gegevens | geen gegevens | |
| Employee representatives Member of the Supervisory Board | less than a year | geen gegevens | geen gegevens |
0.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van FME wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.